Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Mwanasha Merrill, MD
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07588698CT.gov Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07520006CT.gov Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | — | Not Yet Recruiting | — | — | — |
NCT07477366CT.gov Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07097363CT.gov Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT07225439CT.gov Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | — | Not Yet Recruiting | — | — | — |
NCT06824701CT.gov Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Suspended | — | — | — |
NCT07081022CT.gov JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma | — | Recruiting | — | — | — |
NCT06723457CT.gov Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT07073833CT.gov The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06742996CT.gov A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | — | Recruiting | — | — | — |
Show 97 more trialsShow fewer
NCT06564038CT.gov A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | — | Recruiting | — | — | — |
NCT06646666CT.gov ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | — | Not Yet Recruiting | — | — | — |
NCT06634589CT.gov A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | — | Recruiting | — | — | — |
NCT06695013CT.gov Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL | — | Recruiting | — | — | — |
NCT05991388CT.gov A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06230224CT.gov A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06209619CT.gov CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | — | Recruiting | — | — | — |
NCT06104553CT.gov A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | — | Recruiting | — | — | — |
NCT05950334CT.gov FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | — | Completed | — | — | — |
NCT05929716CT.gov An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | — | Withdrawn | — | — | — |
NCT05873712CT.gov Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | — | Recruiting | — | — | — |
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05270057CT.gov Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | — | Active Not Recruiting | — | — | — |
NCT05533775CT.gov A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT05797948CT.gov GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT05202782CT.gov Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05201248CT.gov A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05379647CT.gov Natural Killer (NK) Cell Therapy for B-Cell Malignancies | — | Unknown | — | — | — |
NCT04220008CT.gov Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT04882163CT.gov Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | — | Withdrawn | — | — | — |
NCT04594798CT.gov A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | — | Active Not Recruiting | — | — | — |
NCT04884035CT.gov Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | — | Recruiting | — | — | — |
NCT05097443CT.gov Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT04659044CT.gov Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT05164770CT.gov Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT04665765CT.gov Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04257578CT.gov Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04447716CT.gov An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | — | Active Not Recruiting | — | — | — |
NCT04161248CT.gov Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04245722CT.gov FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | — | Terminated | — | — | — |
NCT04246359CT.gov Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma | — | Unknown | — | — | — |
NCT04023071CT.gov FT516 in Subjects With Advanced Hematologic Malignancies | — | Terminated | — | — | — |
NCT03579927CT.gov CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | — | Withdrawn | — | — | — |
NCT03995147CT.gov Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04045028CT.gov A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT04094142CT.gov Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT04152577CT.gov R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL | — | Unknown | — | — | — |
NCT03740529CT.gov A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | — | Completed | — | — | — |
NCT03677141CT.gov A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03980379CT.gov Pharmacokinetics, Efficacy and Safety of the 304 Injection | — | Unknown | — | — | — |
NCT03670888CT.gov A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients | — | Terminated | — | — | — |
NCT03578198CT.gov Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL) | — | Terminated | — | — | — |
NCT03671018CT.gov A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03424122CT.gov INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | — | Completed | — | — | — |
NCT03467373CT.gov A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | — | Completed | — | — | — |
NCT03373019CT.gov Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | — | Unknown | — | — | — |
NCT03019640CT.gov Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT03206671CT.gov Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents | — | Active Not Recruiting | — | — | — |
NCT03003039CT.gov A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT02898259CT.gov Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma | — | Terminated | — | — | — |
NCT02945215CT.gov A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients | — | Completed | — | — | — |
NCT02933320CT.gov BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | — | Completed | — | — | — |
NCT02741388CT.gov A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | — | Completed | — | — | — |
NCT02843061CT.gov Combination of Rituximab and NK Immunotherapy for B Lymphoma | — | Completed | — | — | — |
NCT02564744CT.gov Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL | — | Completed | — | — | — |
NCT02787239CT.gov Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | — | Completed | — | — | — |
NCT02592876CT.gov Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | — | Terminated | — | — | — |
NCT02456207CT.gov A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | — | Unknown | — | — | — |
NCT02405676CT.gov BNHL-2015 for Children or Adolescents in China | — | Active Not Recruiting | — | — | — |
NCT02584920CT.gov A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma | — | Completed | — | — | — |
NCT02055924CT.gov Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas | — | Terminated | — | — | — |
NCT03218072CT.gov A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas | — | Completed | — | — | — |
NCT01980654CT.gov Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | — | Completed | — | — | — |
NCT01994382CT.gov Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | — | Completed | — | — | — |
NCT01925612CT.gov Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | — | Terminated | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01805037CT.gov Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | — | Terminated | — | — | — |
NCT01729806CT.gov Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma | — | Completed | — | — | — |
NCT01701986CT.gov Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01665768CT.gov Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma | — | Completed | — | — | — |
NCT01695941CT.gov Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01516580CT.gov Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | — | Completed | — | — | — |
NCT01718691CT.gov Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT01421667CT.gov A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01055496CT.gov Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01044745CT.gov Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | — | Terminated | — | — | — |
NCT00946023CT.gov Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | — | Terminated | — | — | — |
NCT00867087CT.gov Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00764517CT.gov Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00849355CT.gov Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk | — | Unknown | — | — | — |
NCT00724971CT.gov Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | — | Completed | — | — | — |
NCT00498043CT.gov A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma | — | Completed | — | — | — |
NCT00515138CT.gov A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant | — | Terminated | — | — | — |
NCT00801216CT.gov High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement | — | Completed | — | — | — |
NCT00455897CT.gov CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00482053CT.gov Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT | — | Terminated | — | — | — |
NCT00413959CT.gov VELCADE,Rituximab,Cyclophosphamide and Decadron | — | Terminated | — | — | — |
NCT00299494CT.gov Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | — | Completed | — | — | — |
NCT00329030CT.gov Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) | — | Completed | — | — | — |
NCT00577629CT.gov Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | — | Completed | — | — | — |
NCT00927797CT.gov Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) | — | Unknown | — | — | — |
NCT00085696CT.gov VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | — | Completed | — | — | — |
NCT00588094CT.gov Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | — | Completed | — | — | — |
NCT00147121CT.gov Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) | — | Completed | — | — | — |
NCT00225212CT.gov Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00210340CT.gov A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Non-Hodgkin Lymphoma
+42 more in the B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →